Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352363 · ClinicalTrials.gov registry record · Phase 3
Randomized Safety Study of CVT-301 Compared to an Observational Control Group
A Phase 3 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
NCT02352363 is a Phase 3 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 408 participants.
The verdict
NCT02352363, a Phase 3 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
Study Summary
This study is a 12-month, open-label, randomized, multicenter study which will evaluate the safety and efficacy of CVT-301 for the treatment of up to 5 OFF episodes per day in Parkinson's Disease (PD) patients experiencing motor fluctuations (OFF episodes) and will include a concurrent observational cohort of PD patients managed using the usual standards of care.
Interventions
- DRUG CVT-301
- OTHER Observational cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02352363
The ClinicalTrials.gov registry entry for NCT02352363 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CVT-301 is the first listed.
NCT02352363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02352363 about?
NCT02352363 is a clinical study titled "Randomized Safety Study of CVT-301 Compared to an Observational Control Group". This study is a 12-month, open-label, randomized, multicenter study which will evaluate the safety and efficacy of CVT-301 for the treatment of up to 5 OFF episodes per day in Parkinson's Disease (PD) patients experiencing motor fluctuations (OFF episodes) and will include a concurrent observational...
What is the current status of trial NCT02352363?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2015-03. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02352363?
The interventions under investigation include: CVT-301 (DRUG), Observational cohort (OTHER).
Who is sponsoring clinical trial NCT02352363?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.